Second Workshop of the European Paediatric Network for Haemophilia Management, 17–19 September 1998 in Vitznau/Switzerland

Adonis-Vournas, Sophie, Athens, Greece* Auberger, Karin, Munich, Germany van den Berg, Marijke, Utrecht, The Netherlands* Chambost, Herve, Marseille, France* Claeyssens, SeÂgoleÁne, Toulouse, France* Glomstein, Anders, Oslo, Norway* Hann, Ian, London, UK Hill, Frank, Birmingham, UK* Kreutz, Wohlhart, Frankfurt, Germany* Ljung, Rolf, MalmoÈ , Sweden* Mori, Pier Giorgio, Genova, Italy Muntean, Wolfgang, Graz, Austria* Petrini, Pia, Stockholm, Sweden* Rosado, Linn, Lisbon, Portugal Scheibel, Elma, Copenhagen, Denmark* Siimes, Martti, Helsinki, Finland* Smith, Owen, Dublin, Ireland Tusell, Joan, Barcelona, Spain*

[1]  Katherine A. High,et al.  Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector , 1999, Nature Medicine.

[2]  Menache.  Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2 , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  R. Ljung,et al.  Port‐A‐Cath usage in children with haemophilia: experience of 53 cases , 1998, Acta paediatrica.

[4]  C. Kessler,et al.  When should prophylactic treatment in patients with haemophilia A and B start?— The German experience , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  J. Sanders,et al.  Implantable venous access devices in children with hemophilia: a report of low infection rates. , 1998, The Journal of pediatrics.

[6]  D. Glück,et al.  Seroconversion of HIV, HCV, and HBV in Blood Donors in 1996 – Risk of Virus Transmission by Blood Products in Germany , 1998, Transfusion Medicine and Hemotherapy.

[7]  R. Ljung.  Can haemophilic arthropathy be prevented? , 1998, British journal of haematology.

[8]  Jurgutis,et al.  The Malmö–Klaipeda WFH twinning programme: a comparative description of the Haemophilia cohorts , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  I. Warrier,et al.  Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experience , 1997, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  James M. Wilson,et al.  Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Moertel,et al.  The use of implantable venous access devices (IVADs) in children with hemophilia. , 1997, Journal of pediatric hematology/oncology.

[12]  S. Kleinman,et al.  The Risk of Transfusion-Transmitted Viral Infections , 1996 .

[13]  V. Blanchette,et al.  Central venous access catheters in children with haemophilia. , 1996, Blood Coagulation and Fibrinolysis.

[14]  K. Khair,et al.  The impact of prophylactic treatment on children with severe haemophilia , 1996, British journal of haematology.

[15]  E. Topol,et al.  Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis , 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[16]  S. Kleinman,et al.  The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. , 1996, The New England journal of medicine.

[17]  A. Vora,et al.  Use of central venous catheters in children with severe congenital coagulopathy , 1995, British journal of haematology.

[18]  F. Oppenheimer,et al.  HCV and organ transplantation , 1995, The Lancet.

[19]  C. Nübling,et al.  Hepatitis C transmission associated with intravenous immunoglobulins , 1995, The Lancet.

[20]  E. Berntorp.  Methods of haemophilia care delivery: regular prophylaxis versus episodic treatment , 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[22]  R. Ljung,et al.  Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia , 1992, Acta paediatrica.

[23]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[24]  K. Kurachi,et al.  Expression of human factor IX in mice after injection of genetically modified myoblasts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. Chader,et al.  Laminin-induced retinoblastoma cell differentiation: possible involvement of a 100-kDa cell-surface laminin-binding protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Palmer,et al.  Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B. , 1989, Blood.

[27]  H. Pettersson,et al.  Magnetic Resonance Imaging in Hemophilic Arthropathy of the Knee , 1987, Acta radiologica.

[28]  H. Pettersson,et al.  Diagnostic Imaging in Hemophilia: Musculoskeletal and Other Hemorrhagic Complications , 1985 .

[29]  H. Pettersson,et al.  Diagnostic Imaging in Hemophilia , 1985, Springer London.